Department of Medical Research, Ministry of Health, Yangon, Myanmar.
Southeast Asian J Trop Med Public Health. 1994 Dec;25(4):710-3.
32 subjects with Plasmodium falciparum gametocytes, and 31 cases with Plasmodium vivax infection from two military hospitals (Lashio, Mandalay) were treated with quinine 600 mg three times a day for 7 days followed by primaquine 45 mg single dose for gametocytes and 45 mg weekly x 8 weeks for vivax malaria. Although screening of red cell glucose-6-phosphate dehydrogenase (G6PD) was done prior to primaquine treatment, G6PD deficient subjects were not excluded from the trial. 20 patients hemizygous for mild G6PD deficiency (GdB- variant), 2 patients hemizygous for severe deficiency (Gd-Myanmar variant) completed the trial. No case of acute hemolysis was observed in all 22 patients with two genotypes of red cell G6PD deficiency status. Therefore, a single dose of primaquine 45 mg and/or weekly for 8 weeks is adequate for the treatment of patients with P. falciparum gametocytes and/or P. vivax malaria ignoring these red cell G6PD enzyme deficient variants in Myanmar.
来自两家军队医院（腊戍、曼德勒）的32名恶性疟原虫配子体感染者和31名间日疟原虫感染者，接受了每日3次、每次600毫克奎宁的治疗，为期7天，随后针对配子体给予45毫克伯氨喹单剂量治疗，针对间日疟给予45毫克伯氨喹每周1次、共8周的治疗。尽管在伯氨喹治疗前进行了红细胞葡萄糖-6-磷酸脱氢酶（G6PD）筛查，但G6PD缺乏的受试者并未被排除在试验之外。20名轻度G6PD缺乏（GdB-变异型）的半合子患者和2名严重缺乏（Gd-缅甸变异型）的半合子患者完成了试验。在所有22名具有两种红细胞G6PD缺乏状态基因型的患者中，均未观察到急性溶血病例。因此，对于缅甸的恶性疟原虫配子体感染者和/或间日疟患者，无论其红细胞G6PD酶缺乏变异型如何，单剂量45毫克伯氨喹和/或每周1次、共8周的伯氨喹治疗就足够了。
